Study of the Effectiveness of Ozurdex for the Control of Uveitis
Proof of Concept Study of the Effectiveness of Ozurdex in Lieu of Oral Corticosteroids for the Control of Active Intermediate and Posterior Uveitis Requiring Immunosuppressive Drug Therapy
Sponsor: Allergan
Listed as NCT02049476, this PHASE4 trial focuses on Uveitis, Intermediate and Uveitis, Posterior and remains completed. Sponsored by Allergan, it has been updated 11 times since 2014, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE4
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE4
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE4
▶ Show 6 earlier versions
-
Aug 2019 — Jan 2021 [monthly]
Completed PHASE4
Status: Recruiting → Completed
-
Mar 2019 — Aug 2019 [monthly]
Recruiting PHASE4
-
Nov 2018 — Mar 2019 [monthly]
Recruiting PHASE4
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE4
First recorded
Jan 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Allergan
- Johns Hopkins University
For direct contact, visit the study record on ClinicalTrials.gov .